NR4A3 and extraskeletal myxoid chondrosarcoma: Twenty-six EMC patients were enrolled; at a median follow-up of 27 months, four of 22 evaluable patients had a RECIST partial response (all of them with EWSR1-NR4A3 fusion), and 55% of the cases showed a certain degree of tumor shrinkage, even though <30% was required by RECIST.